Climb Bio (CLYM) Net Equity Issued and Repurchased (2020 - 2024)
Climb Bio's (CLYM) quarterly Net Equity Issued and Repurchased came in at $41000.0 in Q4 2024, down 85.76% YoY from $288000.0 in Q1 2024, and down 98.19% on a QoQ basis from $2.3 million in Q3 2024.
Climb Bio (CLYM) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Climb Bio (CLYM) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $41000.0 in Q4 2024.
- Quarterly Net Equity Issued and Repurchased fell 85.76% year-over-year to $41000.0 in Q4 2024, while the trailing twelve-month figure through Mar 2025 was $44.2 million (up 5067.13% YoY) and the FY2024 annual result came in at $11.0 million, up 1205.47% from the prior year.
- Net Equity Issued and Repurchased fell to $41000.0 in Q4 2024, from $2.3 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $93.8 million in Q3 2021 to a low of -$93.8 million in Q4 2021.
- A 4-year average of $3.9 million and a median of $105000.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased plunged 2004.37% — and 2024, when it surged 174345.83%.
- Tracing CLYM's Net Equity Issued and Repurchased over 4 years: stood at $4.9 million in 2020, then sank by 2004.37% to -$93.8 million in 2021, then surged by 100.31% to $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024.
- The last three Net Equity Issued and Repurchased figures came in at $41000.0 (Q4 2024), $2.3 million (Q3 2024), and $41.9 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 2.27 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2021 | -93.79 Mn |
| Dec 31, 2021 | -93.79 Mn |
| Sep 30, 2021 | 93.83 Mn |
| Sep 30, 2021 | 93.83 Mn |